Newswise — Clinical decision-making is a complex process, driven by multiple factors, including social and psychological dynamics, peer pressure and even exposure to drug advertising.
Now research from Harvard Medical School shows that when it comes to a physician’s choice of insomnia medication, habit may trump all else. The results suggest that many clinicians choose insomnia drugs somewhat reflexively, based on routine, rather than by taking into account a patient’s symptoms and medical history. Indeed, the analysis showed that a physician’s past prescribing pattern, rather than patient characteristics, was the more potent predictor of what insomnia medication a patient might get.
Findings of the research, based on analysis of 1,105 patients’ medical records and the accompanying clinical notes, appear Feb. 9 in Scientific Reports.
“Our results illuminate the notion that just as everyone else, many physicians are creatures of habit who tend to rely on cognitive shortcuts in their decision-making,” said study first author Andrew Beam, a postdoctoral research fellow in the Department of Biomedical Informatics at HMS. “Doctors are not always as rational as we’d like to believe.”
Insomnia’s economic burden is estimated to top $60 billion a year, a number that doesn’t account for the physical toll of a condition believed to affect as many as 40 percent of Americans. Yet insomnia remains underdiagnosed and poorly treated.As with any other condition, choosing the optimal medication based on individual patient characteristics is critical to successfully resolving symptoms and to averting the many physiologic, psychological and social consequences of insomnia, Beam added. In their analysis, the researchers focused on the two most commonly prescribed drugs: zolpidem, a newer medication with a great efficacy record but associated with side effects such as next-day drowsiness and dizziness, and trazodone, an older drug typically used for depression that is less effective for insomnia but has a well-established safety profile. How and why physicians choose one drug over another remains unclear so the HMS team set out to untangle the factors that drive clinical choice.
Analyzing thousands of patient records and narrative clinical notes and comparing them against each physicians’ prescribing records, the researchers found that a doctor who prescribed one medication in the past was three times as likely to continue prescribing the same drug subsequently.Patients who had symptoms of depression in addition to their insomnia were somewhat more likely than those without depression to receive a prescription for trazodone, the analysis showed. The finding, researchers said, suggests that certain patient characteristics do play some, albeit smaller, role in clinical decision-making.
In addition to the specific findings of the research, the study underscores how electronic medical records—and the wealth of data they contain—can yield intriguing insights into the interplay between physician decision-making and patient characteristics in treatment choices.
“Electronic medical records provide an astounding richness of information at our fingertips that allows us to deconstruct clinical behavior and clinical decision-making in the context of the patient-physician encounter, rather than in isolation,” said study senior author Zak Kohane, chair of the department of biomedical informatics at HMS. “This approach can be used in analyzing treatment decisions for other, more complex conditions.”Other investigators included Uri Kartoun, Jennifer Pai, Arnaub Chatterjee, Timothy Fitzgerald and Stanley Shaw.
The work was supported by the National Institutes of Health Common Fund’s BD2K Center for Excellence grant U54 HG007963 with additional funding by Merck. Harvard Medical SchoolHarvard Medical School (http://hms.harvard.edu) has more than 11,000 faculty working in 10 academic departments located at the School’s Boston campus or in hospital-based clinical departments at 15 Harvard-affiliated teaching hospitals and research institutes: Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Cambridge Health Alliance, Dana-Farber Cancer Institute, Harvard Pilgrim Health Care Institute, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children’s Center, Massachusetts Eye and Ear/Schepens Eye Research Institute, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Spaulding Rehabilitation Network and VA Boston Healthcare System.